

QPS STUDY EXPERIENCE ANTIBODY DRUG CONJUGATES

QPS is a leading full-service global CRO with extensive experience conducting antibody drug conjugate (ADC) research offering comprehensive services to ensure successful drug development. Our experienced and dedicated global team provides unmatched support, from preclinical studies to bioanalysis and all phases of clinical trials.

WHY CHOOSE QPS FOR ONCOLOGY STUDIES WITH ADCS?

1. Expert Global Team

- ▶ **Specialized Expertise:** Our team includes a dedicated framework of board-certified oncologists, experienced clinical research coordinators, project managers, and skilled data analysts.
- ▶ **Patient-Centric Approach:** Powerful associations with efficient study sites across Europe, USA and Asia, innovative patient recruitment strategies, and close links with academia, Site Management Organizations (SMOs), and specialist networks.

2. State-of-the-Art Facilities

- ▶ **Advanced Bioanalysis Laboratories:** Equipped with cutting-edge technology for precise method development and assay execution.
- ▶ **Extensive ADC experience:** Conducting Pharmacokinetic, and Immunogenicity ADC/PDC projects using ELISA, ECL, and (Hybrid) LC-MS/MS.

3. Comprehensive Services

- ▶ **End-to-End Support:** From preclinical studies to bioanalysis, and protocol development to regulatory submissions, QPS handles every aspect of your oncology study.
- ▶ **Customized Solutions:** Tailored study designs to meet the specific needs of oncology research, including biomarker analysis and imaging services.

4. Proven Track Record

- ▶ **Successful Trials:** QPS has conducted Phase I - IV oncology studies across Asia, Europe and the United States.
- ▶ **Broad Range of Cancers:** Including, but not limited to breast, head & neck, lung, and prostate cancer.
- ▶ **Global Reach:** A large worldwide database of investigators ensures high enrollment rates of patients selected according to strict eligibility criteria. In addition, we have the capability to recruit patients in countries with a high prevalence of cancers.

CLINICAL RESEARCH OPERATIONS

- | | | |
|---------------------------------|-----------------------------------|--------------------------------|
| ▶ Project Management | ▶ Data Management & Biostatistics | ▶ Regulatory & Medical Affairs |
| ▶ Clinical Program Management | ▶ Medical Writing | ▶ Safety & Pharmacovigilance |
| ▶ Clinical & Medical Monitoring | ▶ Quality Assurance | ▶ Site Selection & Monitoring |

ONCOLOGY KEY OPINION LEADER (KOL) NETWORK

▶ Europe

- Dr. Mindaugas Jievaltas, Urologist | University Hospital Kaunas/Clinic of Modern Oncology | Lithuania
- Dr. Vincas Urbonas, Medical Oncologist | Early Phase Clinical Trials Lead | National Cancer Institute | Lithuania
- Christina Junvik, Masters Biopharmaceutical Sciences | Early Drug Development in Oncology | Sweden


▶ USA

- Dr. Bruno Fang, Oncologist | Director of Clinical Research at Astera Cancer Care | New Jersey
- Dr. Gordon Brown, Uro-Oncologist | Summit Health/New Jersey Urology | New Jersey
- Dr. Raoul Concepcion, Uro-Oncologist | US Urology Chief Medical Officer | Tennessee

▶ Taiwan

- Dr. Yen-Hwa Chang, Uro-Oncologist | Taipei Veterans General Hospital | Taiwan
- Dr. Peng-Hui Wang Director, Obstetrics and Gynecology | Taipei Veterans General Hospital | Taiwan
- Dr. See-Tong Pang, Uro-Oncologist | Chang Gung Memorial Hospital (CGMH) | Taiwan

ONCOLOGY CLINICAL TRIALS SITE NETWORK LOCATIONS



Pharmacology



Toxicology



DMPK



Bioanalysis



Translational
Medicine



Phase I Clinics



Regulatory &
Medical



Cell Therapy &
Leukopak

Discover how QPS can accelerate your clinical research.

Email: infobd@qps.com | Phone: 512-350-2827 | Website: www.qps.com